Clayton S Lewis

Dr. Clayton S Lewis

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2011 in Cancer Biology & Therapy
Verified
Journal Article
Open access
PDF file
VBVladimir Beljanski
Vladimir Beljanski
CLClayton S Lewis
Clayton S Lewis
CSCharles D. Smith
Charles D. Smith
The balance between the pro-apoptotic lipids ceramide and sphingosine and the pro-survival lipid sphingosine 1-phosphate (S1P) is termed the “sphingosine rheostat”. Two isozymes, sphingosine kinase 1 and 2 (SK1 and SK2), are responsible for phosphorylation of pro-apoptotic sphingosine to form pro-survival S1P. We have previously reported the antitumor properties of an SK2 selective inhibitor, ABC294640, alone or in combination with the multikinase inhibitor sorafenib in mouse models of kidney carcinoma and pancreatic adenocarcinoma. Here we evaluated the combined antitumor effects of the aforementioned drug combination in two mouse models of hepatocellular carcinoma. Although combining the SK2 inhibitor, ABC294640, and sorafenib in vitro only afforded additive drug-drug effects, their combined antitumor properties in the mouse model bearing HepG2 cells mirrored effects previously observed in animals bearing kidney carcinoma and pancreatic adenocarcinoma cells. Combining ABC294640 and sorafenib led to a decrease in the levels of phosphorylated ERK in SK-HEP-1 cells, indicating that the antitumor effect of this drug combination is likely mediated through a suppression of the MAPK pathway in hepatocellular models. We also measured levels of S1P in the plasma of mice treated with two different doses of ABC294640 and sorafenib. We found decreases in the levels of S1P in plasma of mice treated daily with 100 mg/kg of ABC294640 for 5 weeks, and this decrease was not affected by co-administration of sorafenib. Taken together, these data support combining ABC294640 and sorafenib in clinical trials in HCC patients. Furthermore, monitoring levels of S1P may provide a pharmacodynamic marker of ABC294640 activity. See commentary: Sphingosine kinase: A promising cancer therapeutic target

1 January 2013 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Open access
PDF file
TBThomas Hendrix Beckham
Thomas Hendrix Beckham
PLPing Lu
Ping Lu
EJElizabeth E. Jones
Elizabeth E. Jones
TMTucker Marrison
Tucker Marrison
CLClayton S Lewis
Clayton S Lewis
XLXiang Liu
Xiang Liu
Treatment of pancreatic cancer that cannot be surgically resected currently relies on minimally beneficial cytotoxic chemotherapy with gemcitabine. As the fourth leading cause of cancer-related death in the United States with dismal survival statistics, pancreatic cancer demands new and more effective treatment approaches. Resistance to gemcitabine is nearly universal and appears to involve defects in the intrinsic/mitochondrial apoptotic pathway. The bioactive sphingolipid ceramide is a critical mediator of apoptosis initiated by a number of therapeutic modalities. It is noteworthy that insufficient ceramide accumulation has been linked to gemcitabine resistance in multiple cancer types, including pancreatic cancer. Taking advantage of the fact that cancer cells frequently have more negatively charged mitochondria, we investigated a means to circumvent resistance to gemcitabine by targeting delivery of a cationic ceramide (l-t-C6-CCPS [LCL124: ((2S,3S,4E)-2-N-[6′-(1″-pyridinium)-hexanoyl-sphingosine bromide)]) to cancer cell mitochondria. LCL124 was effective in initiating apoptosis by causing mitochondrial depolarization in pancreatic cancer cells but demonstrated significantly less activity against nonmalignant pancreatic ductal epithelial cells. Furthermore, we demonstrate that the mitochondrial membrane potentials of the cancer cells were more negative than nonmalignant cells and that dissipation of this potential abrogated cell killing by LCL124, establishing that the effectiveness of this compound is potential-dependent. LCL124 selectively accumulated in and inhibited the growth of xenografts in vivo, confirming the tumor selectivity and therapeutic potential of cationic ceramides in pancreatic cancer. It is noteworthy that gemcitabine-resistant pancreatic cancer cells became more sensitive to subsequent treatment with LCL124, suggesting that this compound may be a uniquely suited to overcome gemcitabine resistance in pancreatic cancer.

8 August 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
CLClayton S Lewis
Clayton S Lewis
CVChristina Voelkel-Johnson
Christina Voelkel-Johnson
CSCharles D Smith
Charles D Smith
Suppression of c-Myc and RRM2 expression in pancreatic cancer cells by the sphingosine kinase-2 inhibitor ABC294640

1 January 2018
Verified
Book Chapter
Closed access
CLClayton S Lewis
Clayton S Lewis
CVChristina Voelkel-Johnson
Christina Voelkel-Johnson
CSCharles D Smith
Charles D Smith

7 March 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
DUDusten Unruh
Dusten Unruh
BÜBetül Ünlü
Betül Ünlü
CLClayton S Lewis
Clayton S Lewis
XQXiaoyang Qi
Xiaoyang Qi
ZCZhengtao Chu
Zhengtao Chu
VBVladimir Bogdanov
Vladimir Bogdanov
Antibody-based targeting of alternatively spliced tissue factor: a new approach to impede the primary growth and spread of pancreatic ductal adenocarcinoma

25 November 2018 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Closed access
PDF file
CLClayton S Lewis
Clayton S Lewis
HTH. Elnakat Thomas
H. Elnakat Thomas
MOM. A. Orr‐Asman
M. A. Orr‐Asman
LGL. C. Green
L. C. Green
RBR. E. Boody
R. E. Boody
VBVladimir Bogdanov
Vladimir Bogdanov